Published in Am J Med on February 01, 1976
Suppression by superoxide dismutase of immune-complex--induced pulmonary alveolitis and dermal inflammation. Am J Pathol (1981) 1.50
Vasculitis and granulomatosis of the respiratory tract. Thorax (1982) 1.30
Relapsing polychondritis with crescentic glomerulonephritis. Br Med J (1978) 1.25
The ANCA test: its clinical relevance. Ann Rheum Dis (1990) 1.11
Methylprednisolone pulse therapy in the treatment of polyarteritis nodosa. Postgrad Med J (1977) 1.05
Demonstration of inflammatory mediator-induced inflammation and endothelial cell damage in the anterior segment of the eye. Am J Pathol (1983) 0.96
Diverse target antigens recognized by circulating antibodies in anti-neutrophil cytoplasm antibody-associated renal vasculitides. Clin Exp Immunol (1990) 0.93
Pulmonary renal syndromes--a review. Yale J Biol Med (1981) 0.85
Morphologic and immunohistochemical observations in granulomatous glomerulonephritis. Am J Pathol (1987) 0.80
Leukocyte-mediated injury to corneal endothelial cells. A model of tissue injury. Am J Pathol (1984) 0.78
Immunologic mechanisms of parenchymal lung injury. Environ Health Perspect (1984) 0.77
Pulmonary renal syndromes. II. Etiology and pathogenesis. Yale J Biol Med (1982) 0.75
Wegener's granulomatosis and autoantibodies to neutrophil antigens. Ulster Med J (1988) 0.75
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
A computerized summary medical record system can provide more information than the standard medical record. JAMA (1985) 2.77
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (1990) 2.43
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol (1999) 2.29
Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer (1993) 2.10
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res (1993) 1.76
Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol (1989) 1.68
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res (1988) 1.56
Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol (1993) 1.52
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 1.46
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
The impact of chronic disease: a sociomedical profile of rheumatoid arthritis. Arthritis Rheum (1981) 1.32
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res (1997) 1.29
Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol (2001) 1.28
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun (1990) 1.27
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer (2001) 1.26
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer (1994) 1.26
FII haemagglutination test for serum antigammaglobulin factors in arthritides sero-positive and sero-negative by other tests. Ann Rheum Dis (1969) 1.26
Serum antibody to double-stranded RNA and DNA in patients with idiopathic and secondary uveitis. N Engl J Med (1971) 1.23
Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res (1983) 1.23
Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck (1992) 1.22
Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck (2000) 1.21
Health outcomes for a chronic disease in prepaid group practice and fee for service settings. The case of rheumatoid arthritis. Med Care (1986) 1.20
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
Antibody-dependent cell-mediated cytotoxicity in selected autoimmune diseases. J Clin Invest (1976) 1.17
Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol (1993) 1.16
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Formation of "amyloid" fibrils in vitro by action of human kidney lysosomal enzymes on Bence Jones proteins. J Lab Clin Med (1974) 1.16
Totally implantable system for peritoneal access. J Clin Oncol (1984) 1.15
Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene (2001) 1.15
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (1987) 1.13
The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol (1974) 1.13
Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res (2000) 1.13
Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition. Med Care (1998) 1.12
Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol (1994) 1.11
Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol (1994) 1.10
Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem (1990) 1.10
Work disability among persons with musculoskeletal conditions. Arthritis Rheum (1986) 1.09
Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol (1999) 1.08
Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int J Cancer (1975) 1.07
Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153. Br J Cancer (1996) 1.06
Is health care use equivalent across social groups? A diagnosis-based study. Am J Public Health (1983) 1.06
The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum (1978) 1.04
Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest (1990) 1.03
Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I). J Biol Chem (1998) 1.03
Clinical correlates of C1Q-precipitating substances in the sera of patients with leprosy. Am J Trop Med Hyg (1974) 1.03
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer (1999) 1.03
Social and economic impacts of four musculoskeletal conditions. A study using national community-based data. Arthritis Rheum (1983) 1.03
A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. N Engl J Med (1985) 1.02
Increase of L-chain proteins in the sera of patients with systemic lupus erythematosus and the synovial fluids of patients with peripheral rheumatoid arthritis. Arthritis Rheum (1966) 1.01
Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol (1990) 1.01
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer (1998) 1.00
Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer (2004) 1.00
Work disability before and after total hip arthroplasty. Assessment of effectiveness in reducing disability. Arthritis Rheum (1984) 0.99
The information content from renal biopsy in systemic lupus erythematosus. Ann Intern Med (1982) 0.99
Utility of the fluorescent antinuclear antibody test in a single patient. Ann Intern Med (1981) 0.99
Macroglobulin rheumatoid factors directed toward buried antigenic sites of human gamma-globulins. Vox Sang (1966) 0.99
Cell interactions in adoptive immune rejection of a syngeneic tumor. Int J Cancer (1974) 0.99
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res (1993) 0.98
Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo. Br J Cancer (1994) 0.98
Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res (2001) 0.98
Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact (1988) 0.97
Yeast mutants as a model system for identification of determinants of chemosensitivity. Pharmacol Rev (2000) 0.97
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res (2001) 0.97
Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res (1981) 0.95
Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res (1980) 0.94
Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. Arthritis Rheum (1980) 0.93
Uveitis and joint diseases. Clinical findings in 191 cases. Arch Ophthalmol (1967) 0.93
Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol (1984) 0.93
In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest (1993) 0.93
Cellular immunity in mice with simian virus 40-induced mKSA tumors: comparison of three assays of tumor immunity. J Natl Cancer Inst (1974) 0.93
Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol (1993) 0.92
Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J Clin Invest (1995) 0.92
Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer (1997) 0.92
Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer (2000) 0.92
Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res (1992) 0.92
Specificity and reactivity of cytoplasmic and nucleolar antibody in SLE sera. Arthritis Rheum (1969) 0.92
Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol (1985) 0.92
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer (1998) 0.91
Providers as predictors: using outcome predictions in intensive care. Crit Care Med (1986) 0.91
Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer (1994) 0.91
Effect of renal hemotransplantation on the metabolism of the light chains of immunoglobulins. Ann Intern Med (1968) 0.91
Problems associated with the management of pregnancies in patients with systemic lupus erythematosus. J Rheumatol (1980) 0.91
Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus. Arthritis Rheum (1974) 0.91
The cellular pharmacology of oxaliplatin resistance. Eur J Cancer (2002) 0.91
Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues. Br J Cancer (1997) 0.91
Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro. Cancer Res (1990) 0.91
all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clin Cancer Res (1997) 0.90
The nature of U.S. rheumatology practice, 1977. Arthritis Rheum (1981) 0.90
High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol (1985) 0.90
Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter. Genomics (1996) 0.90